Ocular drug delivery system: Approaches to improve ocular bioavailability

Beena Kumari

doi:10.30574/gscbps.2019.6.3.0030

Authors

Beena Kumari School of Medical and Allied Sciences GD Goenka University, Gurugram, India.

DOI:

https://doi.org/10.30574/gscbps.2019.6.3.0030

Keywords:

Ocular drug delivery system (ODDS), Soluble ophthalmic drug insert (SODI), Polyvinyl alcohol (PVA), Polyvinyl pyrrolidone (PVP)

Abstract

Ocular drug delivery system (ODDS) is one of the most challenging tasks faced by pharmaceutical researchers. For a prolonged duration the major barriers in ocular medication are the ability to maintain a therapeutic level of the drug at the site of action. The ophthalmic preparations are available as buffered, sterile and isotonic solution. For the ocular delivery of drugs, several types of dosage forms are prepared and marketed. As drops are easier to administer so the most prescribed dosage form is the eye drop solution. For prolonged therapeutic action ointment, suspensions and gelled systems are also used. Frequent dosing in case of eye drop is the main issue for this system. The new drug delivery systems for this type of delivery is ocuserts, which are designed to eliminate the frequent administration of the drug by releasing the drug at predetermined and predictable rates. For this system the bioerodible implantable elements having multiple layers of different materials with different concentrations of materials are used and this generally include controlled, delayed and or sustained released formulation. The elements generally include an inner layer, or core, including a therapeutic agent, and one or more outer layers made of polymeric materials and this system is also able to prolong the residence time.

Metrics

Metrics Loading ...

References

Zaki I, Fitzgerald p, Hardy JG and Wilson CG. (1999). Comparison of effect of viscosity on the precorneal residence of solution in rabbit and man. Journal of Pharmacy and Pharmacology, 38, 463–466.

Lee VH and Robinson JF. (2009). Review: Topical ocular drug delivery; recent developments and future challenges. Journal of Ocular Pharmacology and Therapeutics, 2, 67.

Sikandar MK, Sharma PK and Visht Sikandar S. (2011). Ocular drug delivery system: an overview. International Journal of Pharmaceutical Sciences and Research, 2, 1168-75.

Saettone MF and Salminen L. (2001). Ocular inserts for topical delivery. Asian Journal of Pharmaceutics, 16, 95–106.

Schoenwald RD. (2003). Ocular Pharmacokinetics/Pharmacodynamics. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker, 260-65.

Neefe CW. (1974). Contact lens for ocular drug delivery. US Patent. 3: 786–812.

Gibaldi M and Perrier D. (1993). Pharmacokinetics: Drugs and the pharmaceutical sciences 2nd edition. Marcel Dekker, New York. 15: 1000-08.

Robinson JC. (2002). Ocular Anatomy and Physiology Relevant to Ocular Drug Delivery. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker. 573-79.

Chien YW. (2003). Novel drug delivery systems. 2nd edition. Marcel DekkerNew York. 301.

Khar RK and Vyas SP. (2002). Targeted and controlled drug delivery novel carrier systems. 1st edition New Delhi: C.B.S. Publishers and Distributors, Inc, 111.

Mainardes RM, Urban MC, Cinto PO and Chaud MV. (2017). Colloidal carriers for ophthalmic drug delivery. Current Drug Targets, 6, 363–371.

Arul kumaran KSG, Karthika K and Padmapreetha J. (2010). Comparative review on conventional and advanced ocular drug delivery formulations, International Journal of Pharmacy and Pharmaceutical Sciences, 2, 1.

Kumar A, Malviya R and Sharma PK. (2016). Recent Trends in Ocular Drug Delivery: A Short Review, European Journal of Applied Sciences, 3, 86-92.

Boarse Manoj B, Kale Sachin S, Bavisker Dheeraj T and Jain Dinesh K. (2013). Comparative review on conventional advanced ocular drug delivery system. Journal of Drug Delivery & Therapeutics. 3(1), 114-1233.

Sampath K, Bhowmik D, Harish G, Duraivel S and kumar P. (2013). Ocular Inserts: A Novel Controlled Drug Delivery System. The Pharma Innovation Journal, 1(12), 1-16.

Saettone MF, Salminen L. (2015). Ocular inserts for topical delivery. Advanced Drug Delivery, 16, 95–106.

Sahane NK, Banarjee SK, Gaikwad DD, Jadhav SL and Throat RM. (2010). Ocular Inserts‐ A Review. Drug Invention, 2, 57–64.

Duvvuri S, Majumdar S and Mitra AK. (2003). Drug delivery to the retina: challenges and opportunities. Expert Opinion and Biological Therapeutics, 3, 45-56.

Keister JC, Cooper ER, Missel PJ, Lang JC and Huger DF. (1991). Limits on optimizing ocular drug delivery. Journal of Pharmacetical Sciences, 80, 50-3.

Lambert G and Guilatt RL. (2005). Current ocular drug delivery challenges. Drug Development Report Industry Overview Details, 33, 1-2.

Souza JG, Dias, Pereira TA, Bernardi DS and Lopez RF. (2014). Topical delivery of ocular therapeutics: carrier systems andphysical methods. Journal of Pharmacy and Pharmacology, 66, 507-30.

Ruponen M and Urtti A. (2015). Undefined role of mucus as a barrier in ocular drug delivery. European Journal of Biopharmaceutics, 96, 442-446.

Nakano M, Lockhart CM, Kelly EJ and Rettie AE. (2014). Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition. Drug Metabolism, 46, 247-60.

Saettone MF, Giannaccini B, Ravecca S, LaMarca F and Tota G. (2015). Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans. International Journal of Pharmaceutics, 20, 187-202.

Sasaki H, Yamamura K, Mukai T, Nishida K and Nakamura M. (2016). Enhancement of ocular drug penetration. Drug Carrier System, 16, 85-146.

Lee VH. (2012). Precorneal, corneal and postcorneal factors. In: Mitra AK (Ed.). Ophthalmic Drug Delivery Systems. New York: Marcel Dekker. 59-82.

Sasaki H, Igarashi Y, Nagano T, Yamamura K, Nishida K and Nakamura J. (2009). Improvement of the ocular bioavailability of timolol by sorbic acid. Journal of Pharmacy and Pharmacology, 47, 17-21.

Lee VH. (2011). Evaluation of ocular anti-inflammatory activity of Buteafrondosa. Journal of Pharmacy and Pharmacology, 11, 79-90.

Tirucherai GS, Dias C and Mitra AK. (2012). Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. Journal of Ocular Pharmacology and Therapeutics, 18, 535-48.

Vandamme TF. (2015). Microemulsions as oculardrug delivery systems: recent developments and future challenges. Journal of Pharmacy and Pharmacology, 21, 15–34.

Kapoor Y and Chauhan A. (2018). Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels. International Journal of Pharmaceutics, 361, 222–229.

Chan J, Maghraby GM, Craig JP and Alany RG. (2017). Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. International Journal of Pharmaceutics, 328, 65–71.

Li CC, Abrahamson M, Kapoor Y and Chauhan A. (2018). Timolol transport from microemulsions trapped in HEMA gels. Journal of Colloidal Interface and Sciences, 315, 297–306.

Buech G, Bertelmann E, Pleyer U, Siebenbrodt I and Borchert HH. (2017). Formulation of sirolimus eye drops and corneal permeation studies. Journal of Ocular Pharmacology and Therapeutics, 23, 292–303.

Kaur IP and Kanwar M. (2018). Ocular preparations: The formulation approach. Drug Development and Industrial Pharmaceutics, 28, 473–93.